Y Intercept Hong Kong Ltd Acquires Shares of 2,344 TransMedics Group, Inc. (NASDAQ:TMDX)

Y Intercept Hong Kong Ltd bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, HoldingsChannel reports. The fund bought 2,344 shares of the company’s stock, valued at approximately $368,000.

Other hedge funds have also made changes to their positions in the company. Driehaus Capital Management LLC increased its stake in shares of TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after buying an additional 202,867 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in TransMedics Group by 5.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its stake in shares of TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after acquiring an additional 64,360 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. lowered their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research note on Tuesday, October 29th. Canaccord Genuity Group lowered their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $126.80.

TransMedics Group Price Performance

TMDX opened at $64.22 on Tuesday. The stock has a market cap of $2.16 billion, a P/E ratio of 68.32 and a beta of 2.06. TransMedics Group, Inc. has a 12 month low of $63.42 and a 12 month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a fifty day simple moving average of $94.37 and a 200 day simple moving average of $130.78.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter last year, the firm earned ($0.12) EPS. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. On average, research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Activity

In related news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 19,417 shares of company stock worth $2,240,738 over the last quarter. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.